Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31345511 | 1.00 | PIK3CA (0.37) | PIK3CACYP3A4TSHRMAPK1POLB | |
| SCHEMBL11993969 | 0.84 | PIK3CA (0.41) | PIK3CACYP3A4TSHRPOLBRECQL | |
| SCHEMBL21372397 | 0.83 | CYP3A4 (0.37) | PIK3CACYP3A4TSHRMAPK1POLB | |
| SCHEMBL38665916 | 0.83 | PIK3CA (0.41) | PIK3CACYP3A4TSHRMAPK1POLB | |
| SCHEMBL215544 | 0.83 | PIK3CA (0.41) | PIK3CACYP3A4TSHRMAPK1POLB | |
| SCHEMBL22833318 | 0.81 | PIK3CA (0.44) | PIK3CAMAPTCASP1 | |
| SCHEMBL15339519 | 0.79 | RECQL (0.38) | POLBRECQLMAPTGAAALDH1A1 | |
| SCHEMBL1674716 | 0.78 | BRAF (0.36) | CYP3A4TSHRMAPK1POLBMAPT | |
| SCHEMBL29939860 | 0.76 | P2RX7 (0.36) | CYP3A4TSHRMAPK1TERT | |
| SCHEMBL1559757 | 0.76 | P2RX7 (0.36) | CYP3A4TSHRMAPK1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536673-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2025-04-16 | — | — | EP | disclosed |
| US-20230416287-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-28 | — | — | US | disclosed |
| WO-2023238064-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-12-14 | — | — | WO | disclosed |
| US-11001569-B2 | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-11 | — | — | US | disclosed |
| WO-2017125534-A1 | NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-27 | — | — | WO | disclosed |
| US-8436000-B2 | Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2307024-B1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20110124662-A1 | Substituted Carbamate Derivatives as Modulators of Corticotropin-Releasing Factor Receptor Activity | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| EP-2307024-A1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010014687-A1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124662-A1 | Substituted Carbamate Derivatives as Modulators of Corticotropin-Releasing Factor Receptor Activity | CRH, CRHR1, CRHR2 | PIK3CA 2987/4885CYP3A4 3580/4885TSHR 67/4885 |
| US-11001569-B2 | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | PIK3CA 422/4885CYP3A4 3245/4885TSHR 4112/4885 |
| US-20230416287-A1 | Chemical Compounds | SCN8A, TRPV1, SCN10A | PIK3CA 752/4885CYP3A4 2294/4885TSHR 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.